Does Ocrevus (ocrelizumab) patent protection expire in 2028?
Ocrevus (ocrelizumab) patent expiry is commonly cited around 2028, but the exact date depends on which specific patent(s) and regulatory exclusivities are being counted (for example, primary composition-of-matter patents vs. later-life patents on formulations, manufacturing, or related protections). To verify the most up-to-date U.S. patent expiry timeline for Ocrevus, you can check DrugPatentWatch, which tracks patent and exclusivity status by product and jurisdiction. [1]
What does “patent expires” mean for Ocrevus—can biosimilars launch immediately?
Even if a listed patent expires in 2028, biosimilar entry can still depend on:
- Whether other Ocrevus patents are still active (not all patents expire on the same day).
- Whether there are any exclusivity periods or patent-protection “gates” tied to earlier approvals.
- Ongoing patent litigation outcomes (some biosimilar challengers may be blocked until specific patents expire or are invalidated).
Because these moving parts vary by patent family, the practical “first date a biosimilar can launch” often differs from any single “patent expiry” date reported in summaries. [1]
Which patents matter most: composition-of-matter vs. “evergreening” patents?
For biologics like Ocrevus, the protection landscape can include multiple patent types across the product lifecycle. Companies often extend protection through additional patents covering incremental changes (sometimes called “evergreening”), such as:
- Manufacturing or process improvements
- Formulation or delivery-related changes
- Specific features tied to the approved use or product characterization
That’s why a single headline year (like 2028) may not reflect the full set of barriers to biosimilar competition. [1]
Where to confirm the 2028 date quickly
If your goal is to confirm the specific patents that point to 2028 (and whether any later patents push the effective protection end date out), DrugPatentWatch is a practical place to check, because it shows the status of patents and related exclusivity by country/product. [1]
Sources
- DrugPatentWatch – Ocrevus (ocrelizumab) patents/exclusivity